SARASOTA, Fla., May 26, 2016 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has appointed Steve Miley, M.D., to serve as its Chief Medical Officer. Dr. Miley, currently a practicing physician and a member of the Company's...
SARASOTA, Fla., May 19, 2015 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by Southern Research in Birmingham, Alabama, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven...
SARASOTA, Fla., March 12, 2015 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has expanded upon a research collaboration with Dr. Leona Gilbert at the Department of Biological and Environmental Sciences of the University of Jyvaskyla, Finland to...
SARASOTA, Fla., Dec. 11, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced that the Company has submitted an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) to conduct a Phase 1/2a study of Nu-3 as a...
SARASOTA, Fla., Sept. 11, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent and Trademark Office has issued a 'Notice of Allowance' for patent application 11/673,486 entitled 'Oligonucleotide-Containing Pharmacological Compositions And Their Uses'. The...
SARASOTA, Fla., June 18, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has raised a total of $5.5 million, before fees and expenses, through a Series C Preferred stock offering from a group of accredited investors. ...
SARASOTA, Fla., Jan. 8, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has elected Geoffrey F. Cox, Ph.D., to serve on its board of directors. Dr. Cox, currently an independent consultant to the Biotechnology and Life...
SARASOTA, Fla., Oct. 9, 2013 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has entered into a strategic advisory agreement with H.C. Wainwright & Co., LLC ("Wainwright"). Pursuant to this agreement, Wainwright will assist Lakewood-Amedex in exploring various licensing,...
SARASOTA, Fla., Sept. 10, 2013 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that in vitro studies demonstrate that its bisphosphocin class of antimicrobials is highly effective at killing bacteria established in biofilm. The results will be presented in...
SARASOTA, Fla., July 31, 2013 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by ImQuest BioSciences of Fredrick, MD, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven...